health π¦ Singapore lab working on Ebola vaccine doses
Hilleman Labs in Singapore will develop and produce Bundibugyo ebolavirus vaccine doses for clinical trials. The collaboration is between Hilleman Laboratories and Norway's CEPI, focusing on affordability for outbreak areas. With up to $8.5 million in CEPI funding, the vaccine development uses the rVSV platform. MSD will advise Hilleman, adapting a process from their Zaire ebolavirus vaccine. This work aims to speed up the response to large Ebola outbreaks, mainly in the Democratic Republic of the Congo. π¦